Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse
Expert Opinion on Drug Metabolism & Toxicology June 18, 2021 M. Luz, D. Mash 30 citations
Ibogaine, a psychoactive alkaloid from the West African shrub Tabernanthe iboga, has a history of use by indigenous cultures for fatigue, hunger, and religious ceremonies. First isolated in 1901, it was marketed in France until 1970 as a neuromuscular stimulant. Since the 1960s, anecdotal reports have suggested benefits for treating opioid abuse, though it was later classified as a Schedule I substance by the FDA. While the benefit-risk ratio for opioid withdrawal under medical supervision appears favorable, published reports of drug-related deaths and safety concerns continue to impede development.